BMO Capital analyst Evan David Seigerman maintains AbbVie (NYSE:ABBV) with a Outperform and lowers the price target from $195 to $180.
BMO Capital Maintains Outperform on AbbVie, Lowers Price Target to $180
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.